BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

CHEMICON International, Inc. (SERO) Licenses Its Patented Amplifluor Technology For Cancer Diagnostics To OncoMethylome Sciences S.A.


10/19/2005 5:13:10 PM

ATLANTA--(BUSINESS WIRE)--March 30, 2005--Serologicals Corporation (NASDAQ: SERO) announced today that Chemicon International, Inc., its wholly-owned subsidiary and OncoMethylome Sciences S.A.("OMS") have entered into an agreement pursuant to which OMS has licensed Chemicon's patented fluorescent detection technology, Amplifluor(R), for the clinical development of diagnostic assays detecting DNA methylation patterns. DNA methylation is one of the primary biological mechanisms that determine gene expression. Thus, DNA methylation is an essential control mechanism for the normal development and cellular functioning of organisms. Abnormal DNA methylation, or hyper-methylation of DNA, incorrectly switches off critical genes, such as tumor suppressor genes or DNA repair genes, allowing cancers to develop and progress. DNA methylation patterns act as specific markers for disease and measuring the differences in DNA methylation patterns between healthy and diseased states provides a reliable and sensitive method for identifying disease and disease progression.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->